Cover Image

PRDI-BF1 and PRDI-BF1β isoform expressions correlate with disease status in multiple myeloma patients

Gabriele Buda, Francesca Guerrini, Sara Galimberti, Enrico Orciuolo, Simone Pacini, Elisa Mazzantini, Mario Petrini
  • Gabriele Buda
    Department of Clinical and Experimental Medicine, U.O. Hematology, University of Pisa, Italy | ga.buda@libero.it
  • Francesca Guerrini
    Department of Clinical and Experimental Medicine, U.O. Hematology, University of Pisa, Italy
  • Sara Galimberti
    Department of Clinical and Experimental Medicine, U.O. Hematology, University of Pisa, Italy
  • Enrico Orciuolo
    Department of Clinical and Experimental Medicine, U.O. Hematology, University of Pisa, Italy
  • Simone Pacini
    Department of Clinical and Experimental Medicine, U.O. Hematology, University of Pisa, Italy
  • Elisa Mazzantini
    Department of Clinical and Experimental Medicine, U.O. Hematology, University of Pisa, Italy
  • Mario Petrini
    Department of Clinical and Experimental Medicine, U.O. Hematology, University of Pisa, Italy

Abstract

Human positive regulatory domain I binding factor 1 (PRDI-BF1 or BLIMP-1) is a transcription factor that acts as a master regulator and has crucial roles in the control of differentiation and in maintaining survival of plasma cells (PC). The PRDM1 gene, which codifies for PRDI-BF1, contains an alternative promoter capable of generating a PRDI-BF1 deleted protein (called PRDI-BF1β), which lacks 101 amino acids comprising most of the regulatory domain. PRDI-BF1β has been detected in relevant quantities especially in multiple myeloma cell lines (U266 and NCI- H929). The first aim of the study was to compare, using real time polymerase chain reaction (RT-PCR), the levels of PRDI-BF1 and PRDI-BF1β in myeloma patients and in normal human bone marrow. The second step was the examination of the expression of PRDI-BF1 and PRDI-BF1β isoform depending on disease status and treatment response. We demonstrate the correlation of PRDI-BF1 and the shorter PRDI-BF1β isoform protein levels with the clinical evolution and the management of myeloma patients.

Keywords

Hematology, Multiple Myeloma, multi drug resistance.

Full Text:

PDF
HTML
Submitted: 2017-04-23 23:33:04
Published: 2017-12-22 10:34:25
Search for citations in Google Scholar
Related articles: Google Scholar
Abstract views:
241

Views:
PDF
35
HTML
42

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM


Copyright (c) 2017 Gabriele Buda

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 
© PAGEPress 2008-2018     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185     •     Privacy